AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02461979 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The VDR genotype
Description: The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
Study NCT04489355 — intervention group
Intervention type: PROCEDURE
Intervention: coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)
Study NCT02646774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Injection
Study NCT03664791 — intervention group
Intervention type: PROCEDURE
Intervention: Vanguard Rocc
Description: Patient operated with the Vanguard Rocc knee prosthesis
Study NCT04390724 — intervention group
Intervention type: DEVICE
Intervention: Y90 radioembolization
Description: Patients with HCC who are eligible to receive standard-of-care Y90 radioembolization and are hepatic resection candidates with inadequate future liver remnant
Study NCT01220531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured Thymus Tissue
Description: Potential recipients of cultured thymus tissue are screened for eligibility. The thymus tissue (from an unrelated donor), the donor, and the donor's mother are screened for safety. Cultured thymus tissue is implanted under general anesthesia in the operating room. Cultured thymus tissue is placed into the subject's quadriceps. Two to three months post-implantation, if medically stable, subjects may undergo an allograft biopsy. Subjects undergo laboratory testing for approximately one-year post-implantation. At approximately year 2 post-implantation, subjects are contacted for data collection.
Study NCT02846571 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Human Pancreatic Islet Transplantation
Description: Human pancreatic islet transplantation in the eye anterior chamber of legally blind patients with insulin-dependent type 1 or type 2 diabetes
Study NCT03518606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab + metronomic Vinorelbine
Description: Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy
Study NCT04362007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Treatment of ASTX660 for r/r PTCL and r/r CTCL
Study NCT04362007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Treatment of ASTX660 for r/r ATLL
Study NCT04362007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Treatment of ASTX660 for r/r PTCL
Study NCT04326140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mirror therapy
Description: The affected side wears the machine, assists by the machine, and performs the same action with the good hand. According to the posture condition, selects two suitable actions in the three actions (all fingers open, all fingers close, all fingers open and close). The action is 10 minutes each.
Study NCT03167970 — intervention group
Intervention type: DEVICE
Intervention: Pill cam
Description: Patient is asked to swallow the esophageal capsule.
Study NCT03167970 — intervention group
Intervention type: OTHER
Intervention: EGD
Description: Patient will undergo standard EGD
Study NCT03334851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835375
Description: Intravenous (IV) or subcutaneous (SC) administration. Subjects will receive one or two doses. Doses will be ascending and determined by emerging data.
Study NCT00619801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: Levocetirizine dihydrochloride 1.25 mg oral drops formulation (5 drops containing 5mg/mL) dosed twice a day for 2 weeks
Study NCT00619801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral drops (5 drops) dosed twice a day for 2 weeks.
Study NCT04396431 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: education
Description: The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy. The program was prepared by the researchers in consideration of the SunSmart Program implemented in Australia, the SunWise School Program developed by the United States Environmental Protection Agency. The program included various educational tools such as a sun protection story, activity book, PowerPoint presentations, cartoons, and puzzles.~Refresher training was conducted 15 days, 1 month, and 2 months after the initial training. Sun protection behavior and self-efficacy of the children were evaluated at the beginning of the study and six months after the program. As gifts to support their sun protection behavior, the children were given an FDA-approved sunscreen with 50+ SPF, a white cotton short-sleeved T-shirt as protective clothing, sunglasses with 100% UV protection, and a wide-brimmed hat.
Study NCT02172742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: BIA 2-093 1200 mg once-daily
Study NCT02172742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT02172742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
Study NCT02172742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Digoxin
Description: Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
Study NCT01150981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: One 8mg capsule daily for 6 weeks.
Study NCT01150981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule daily for 6 weeks.
Study NCT01119885 — intervention group
Intervention type: DRUG
Intervention: fentanyl matrix
Description: Knee osteoarthritis, starting with 12mcg/h (flexible dose)
Study NCT01119885 — intervention group
Intervention type: DRUG
Intervention: fentanyl matrix
Description: Hip osteoarthritis, starting with 12mcg/h (flexible dose)
Study NCT04285879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction using Delfi Personalized Tourniquet System
Description: The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device following the Owens Recovery Science Protocol
Study NCT03330769 — intervention group
Intervention type: DRUG
Intervention: New course of treatment
Description: Prescription of new course of NSAIDs (monotherapy), steroid intra-articular injections (monotherapy), conventional DMARDs, biologic DMARDs, including switches or dose augmentations, indicated by the treating rheumatologist according to usual clinical practice.
Study NCT03334851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.
Study NCT00503802 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Turbinate Reduction
Description: Radiofrequency Turbinate Reduction
Study NCT00503802 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham RF
Description: The steps of the procedure are as follows: 1) application of topical anesthetic to the turbinate mucosa bilaterally; 2) injection of 1.0 ml of lidocaine 1% with epinephrine 1:100,000 with a 30-gauge needle into each inferior turbinate anteriorly; 3) delay five minutes for local anesthetic to take full effect; 4) re-insertion of the anesthetic needle to check for complete anesthesia on one side, and injection of another 1.0 ml of lidocaine 1% with epinephrine 1:100,000 5) placement of the radiofrequency electrode (23-gauge, 1 cm long) into the inferior turbinate; 6) delivery of 300 Joules of radiofrequency energy to the turbinate over 29 seconds (no energy will be delivered in sham procedure)7) placement of a cotton pledget (soaked in oxymetazoline solution 0.05%) against the treatment site 8) repeat steps 3 - 8 for the contra-lateral inferior turbinate; 9) removal of the cotton pledgets after several minutes; and 11) observation of hemostasis.
Study NCT01948453 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garlic
Description: Garlic tablet in adjunct to medical treatment
Study NCT02388204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantable spinal cord stimulation
Description: Implantation of SCS electrode and pulse generator
Study NCT03728660 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual bioptic magnification with large field of view
Description: The intervention device will have a larger field of vision than the legacy device and the intervention device will also have a virtual bioptic telescope mode not found on the legacy device. The user will be able to adjust the size of the virtual bioptic telescope and the amount of magnification with a touch pad on the side of the head-mounted display (HMD).
Study NCT03728660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual bioptic magnification with large field of view
Description: The intervention device will have a larger field of vision than the legacy device and the intervention device will also have a virtual bioptic telescope mode not found on the legacy device. The user will be able to adjust the size of the virtual bioptic telescope and the amount of magnification with a touch pad on the side of the head-mounted display (HMD).
Study NCT03728660 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Full field magnification with small field of view
Description: Comparison intervention with user-controlled full field magnification with a smaller field size shared by legacy head-mounted devices. User can control amount of magnification
Study NCT03728660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full field magnification with small field of view
Description: Comparison intervention with user-controlled full field magnification with a smaller field size shared by legacy head-mounted devices. User can control amount of magnification
Study NCT02419053 — intervention group
Intervention type: OTHER
Intervention: Surgical Safety Checklist
Description: An Ontario hospital-wide introduction of a surgical safety checklist based on the WHO guidelines, as mandated by the Ontario Ministry of Health
Study NCT04824235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amniotic Chorion Membrane and Bio-Oss xenograft
Description: Bioxclude Amniotic Chorion Membrane with xenograft (Bio-Oss) for ridge preservation
Study NCT04824235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic Chorion Membrane only
Description: Bioxclude Amniotic Chorion Membrane only
Study NCT01598883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: 150 U/kg
Study NCT01598883 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Heparin
Description: 150 U/kg
Study NCT01598883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATryn
Description: 1000 IU
Study NCT01598883 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ATryn
Description: 1000 IU
Study NCT01846676 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Communication Education Program
Description: The program called Active Communication Education (ACE), that is a semistructured rehabilitation program for people with hearing loss, which aims to improve rehabilitation of hearing aids users by a strategy based on problem solution.
Study NCT01846676 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
Study NCT00523705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: 10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
Study NCT00523705 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets matched to drug
Study NCT01275612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell infusion
Description: The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.
Study NCT02421731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training
Description: Patients will receive 12 training sessions, lasting for an hour with 30 minutes of real walking time, over 4 weeks (3 sessions/week) of RAGT. Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. During the first session we will set these parameters according to subject characteristics and demand level. As training will progress, adjustments in the three parameters previously described will be performed.
Study NCT02421731 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: The control group will receive 12 conventional therapy sessions over 4 weeks (3 sessions/week), that will focus on gait training. Subjects will receive 1 hour of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that, assisted over-ground walking training will be performed.
Study NCT04671784 — intervention group
Intervention type: OTHER
Intervention: EUS-E
Description: EUS-E
Study NCT00725348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talarozole
Description: 1.0 mg oral dose per day
Study NCT01419613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Breast cancer survivors will receive general information on how to adopt healthy lifestyle behaviors.
Study NCT01419613 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: The control group of breast cancer survivors will receive counseling on how to increase their level of physical activity.
Study NCT02904005 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized assessment on depressed patients
Description: At inclusion, socio-demographic characteristics, main life events, psychopathology (comorbidity, personality dimensions, characterisation of SB) and biological sample will be performed by psychiatrist and nurse. Investigators will retrieve the results of biological assays routinely made as part of standard collect biological results routinely done for all depressed patient.~At follow-up (3 months, 6 months, 12 months), they will assess thymic state, occurrence of suicidal ideation and suicide attempt and environmental stressors. In case of non response, the general physician or the psychiatrist in charge of the patient will be contacted to assess the occurrence of SB during the year. In case of death or absence of clinical information, a request for cause of death certificate will be carried out through tne National Institute of Health and Medical research (INSERM) Unit 1018 / Epidemiological center on medical causes of death (CépiDc).
Study NCT02850861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Condylar reductor
Description: A new surgical instrument was designed to assist the surgeons to perform condylar fracture reduction.
Study NCT01932320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813: Formulation A
Description: Participants will receive JNJ-40411813 100 mg hard gelatin capsule orally (by mouth) as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
Study NCT03012256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardio-respiratory management model
Description: Includes scheduled nurse-led self-management support (based on a training program, and tool-kit), advanced care and goal planning, clinical pharmacist education reconciliation, team case rounds, Situation, Background, Assessment and Recommendation (SBAR) communication protocol with primary care, and a standardized transition package
Study NCT03211416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03211416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03211416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT02345694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effective CPAP
Description: Effective Continuous Positive Airway Pressure auto-regulated, worn all night long during 8 weeks
Study NCT02345694 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sub-therapeutic CPAP
Description: Sub-therapeutic Continuous Positive Airway Pressure (Sham-CPAP) worn all night long during 8 weeks
Study NCT04300114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib capsules po. 150 mg twice daily
Study NCT01932320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813: Formulation B
Description: Participants will receive JNJ-40411813 100 mg immediate release tablet orally as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
Study NCT04300114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules po. twice daily
Study NCT01988805 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Study NCT01782144 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NutriSystem portion-controlled pre-packaged meals
Study NCT01782144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NutriSystem portion-controlled pre-packaged meals
Study NCT02381249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
Study NCT02381249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
Study NCT02381249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
Study NCT02381249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
Study NCT01932320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813: Formulation C
Description: Participants will receive JNJ-40411813 100 mg nanosuspension orally as a single dose for Part 1 (Period 1, Period 2, and Period 3).
Study NCT01932320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Participants will receive ketoconazole 200 mg tablet orally twice daily with food from Day 6 to Day 14 in Part 3.
Study NCT04302701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dichoptic treatment using virtual reality
Description: Dichoptic visual training will be performed with the patient wearing his spectacles using the computer game included in Vivid Vision (Vivid Vision, San Francisco, USA) which will be run in the Oculus Rift OC CV1 virtual reality head mounted display (Oculus VR, Menlo Park, California, USA). Each subject will have 20 treatment sessions, divided into 1 hour-sessions performed twice a week for 10 weeks. Each session will be 60 minutes. Adherence to the treatment regimen will be assessed by the number of hours spent in training at the end of 5th week.
Study NCT04302701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: Patients in the control group will be instructed to continue wearing spectacles if required. Patients will be prescribed two continuous hours of daily patching with at least one hour of near activities during patching. Adhesive skin patches will be provided by the study. The parent/patient will be instructed to spend at least one of the hours of patching time each day performing eye-hand coordination activities at near.